Abstract dotted data landscape in pink and blue

Optimizing DMC Management in Phase III Trials

1 minute read

Published: October 14th, 2025

Navigating multi-therapeutic Phase III studies is complex. From strict blinding protocols to scheduling senior DMC members across multiple time zones, the challenges are significant. Phastar’s tailored approach ensures that every deliverable is managed efficiently, securely, and with the highest statistical rigor. 

Key highlights from our case study: 

  • Full-Spectrum DMC Management: Over 45 blinded and unblinded outputs per meeting, including demographics, disposition, safety, and ad hoc efficacy analyses. 
  • Secure Data Handling: Transitioned from problematic shared folders to compliant sFTP systems, ensuring reliable and secure data sharing. 
  • Process Optimization: Streamlined workflows, facilitated smooth team handovers, and proactively resolved data quality issues. 
  • Stakeholder Integration: Seamlessly collaborated with sponsor and vendor teams, adding value without complexity. 

Complete the form below to read the full case study

Related articles

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

October 29th, 2026 1 minute read

Interim analyses and safety reviews play a critical role in clinical trial oversight, providing decision-makers with ...

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

July 20th, 2026 1 minute read

Designing a first-in-human study is challenging. Designing one for a novel reproductive therapy with limited prior da...

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

July 20th, 2026 1 minute read

Accelerating clinical development requires more than speed, it demands a careful balance between innovation, scientif...